(EMAILWIRE.COM, August 11, 2018 ) The bioburden testing market is expected to reach $565.6 Million by 2019 from $354.4 Million in 2014, at a CAGR of 9.8% from 2014 to 2019. Major factors driving the growth of this market include the growing medical device industry, changing trends in the pharmaceutical and biotechnology industries, increasing food safety concerns to boost this market, strong trend of R&D investments in life sciences, and increasing product recalls due to microbial contamination. However, high cost of instruments and complex and time-consuming regulatory standards which lengthen the approval process in some countries may hinder the growth of this market. Emerging economies such as India and China present an array of opportunities for this market.

Know More: https://www.marketsandmarkets.com/Market-Reports/bioburden-testing-market-17983056.html

North America dominated the microbial limit testing market, with the U.S. accounting for a major market share in 2014. However, Asia is poised to grow at the highest CAGR during the forecast period. Growth in the Asian market will be driven by factors such as strong investments and rapid growth in the pharmaceutical and biotechnology industries, growing medical device industry, government initiatives and rising awareness for bioburden testing in various Asian countries.

Prominent players in the bioburden testing market are Charles River Laboratories International, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), SGS S.A. (Switzerland), WuXi PharmaTech (Cayman) Inc. (China), Merck & Co., Inc. (U.S.), Becton, Dickinson and Company (U.S.), North American Science Associates, Inc. (NAMSA) (U.S.), Nelson Laboratories (U.S.), Pacific Biolabs (U.S.), and ATS Labs, Inc. (U.S.).

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=17983056